TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
Background Transforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses. However, TGFβ also plays multiple roles in normal tissues, particularly during organogenesis,...
主要な著者: | Canè, S, Van Snick, J, Uyttenhove, C, Pilotte, L, Van den Eynde, BJ |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
BMJ Publishing Group
2021
|
類似資料
-
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance
著者:: Hennequart, M, 等
出版事項: (2017) -
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance.
著者:: Hennequart, M, 等
出版事項: (2017) -
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
著者:: Lecomte, S, 等
出版事項: (2023) -
TGF-β in transplantation tolerance.
著者:: Regateiro, F, 等
出版事項: (2011) -
TGF-β in transplantation tolerance
著者:: Regateiro, F, 等
出版事項: (2011)